Milestones in Parkinson's disease—Clinical and pathologic features
Identifieur interne : 001561 ( Main/Exploration ); précédent : 001560; suivant : 001562Milestones in Parkinson's disease—Clinical and pathologic features
Auteurs : Glenda Halliday [Australie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Matthew Stern [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-05.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Asymptomatic, Dopamine (metabolism), History, 20th Century, History, 21st Century, Humans, Lewy Bodies (pathology), Lewy bodies, Lewy body, Nervous system diseases, Neurons (metabolism), Neurons (pathology), Parkinson Disease (complications), Parkinson Disease (history), Parkinson Disease (pathology), Parkinson Disease (therapy), Parkinson disease, neuropathology, preclinical Parkinson's disease, α‐synuclein.
- MESH :
- chemical , metabolism : Dopamine.
- complications : Parkinson Disease.
- history : Parkinson Disease.
- metabolism : Neurons.
- pathology : Lewy Bodies, Neurons, Parkinson Disease.
- therapy : Parkinson Disease.
- History, 20th Century, History, 21st Century, Humans.
Abstract
The identification of the widespread deposition of fibrillized α‐synuclein in Lewy bodies and Lewy neurites in the brains of patients with Parkinson's disease in 1997 has had a profound impact on how the disease is now conceptualized. The previous focus on the loss of the dopaminergic nigrostriatal system, the concept of subcortical dementia, and the idea that Parkinson's disease was dominated by motor impairment have all given way to research assessing more diverse brain regions, clinical symptoms, and phenotypes. It is now recognized that Parkinson's disease is more than just a loss of midbrain dopaminergic neurons in association with Lewy bodies. There are now several theories on how the disease develops and progresses currently being validated in a variety of studies, although many of these theories have yet to incorporate the phenotypic clinical and pathological changes associated with age. A particularly exciting new area of research involves the cell‐to‐cell transmission of pathogenic proteins. The recent consensus definition of Parkinson's disease dementia will allow its pathologic substrates to be determined. These advances have progressed to a stage where the preclinical stages of Parkinson's disease and its specific signs and symptoms are being predicted and tested clinically. Such strategies herald a future wave of preventive strategies for Parkinson's disease and its clinical symptoms. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23669
Affiliations:
- Australie, Royaume-Uni, États-Unis
- Angleterre, Grand Londres, Pennsylvanie
- Londres, Sydney
- National Hospital for Neurology and Neurosurgery
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000565
- to stream Istex, to step Curation: 000565
- to stream Istex, to step Checkpoint: 000293
- to stream PubMed, to step Corpus: 001176
- to stream PubMed, to step Curation: 001176
- to stream PubMed, to step Checkpoint: 001245
- to stream Ncbi, to step Merge: 003252
- to stream Ncbi, to step Curation: 003252
- to stream Ncbi, to step Checkpoint: 003252
- to stream Main, to step Merge: 001614
- to stream PascalFrancis, to step Corpus: 000583
- to stream PascalFrancis, to step Curation: 002735
- to stream PascalFrancis, to step Checkpoint: 000511
- to stream Main, to step Merge: 001B01
- to stream Main, to step Curation: 001561
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Milestones in Parkinson's disease—Clinical and pathologic features</title>
<author><name sortKey="Halliday, Glenda" sort="Halliday, Glenda" uniqKey="Halliday G" first="Glenda" last="Halliday">Glenda Halliday</name>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D3143478950ED27D311D670FCE4BA2216869276B</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23669</idno>
<idno type="url">https://api.istex.fr/document/D3143478950ED27D311D670FCE4BA2216869276B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000565</idno>
<idno type="wicri:Area/Istex/Curation">000565</idno>
<idno type="wicri:Area/Istex/Checkpoint">000293</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Halliday G:milestones:in:parkinson</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21626546</idno>
<idno type="wicri:Area/PubMed/Corpus">001176</idno>
<idno type="wicri:Area/PubMed/Curation">001176</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001245</idno>
<idno type="wicri:Area/Ncbi/Merge">003252</idno>
<idno type="wicri:Area/Ncbi/Curation">003252</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003252</idno>
<idno type="wicri:Area/Main/Merge">001614</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0264640</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000583</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002735</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000511</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Halliday G:milestones:in:parkinson</idno>
<idno type="wicri:Area/Main/Merge">001B01</idno>
<idno type="wicri:Area/Main/Curation">001561</idno>
<idno type="wicri:Area/Main/Exploration">001561</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Milestones in Parkinson's disease—Clinical and pathologic features</title>
<author><name sortKey="Halliday, Glenda" sort="Halliday, Glenda" uniqKey="Halliday G" first="Glenda" last="Halliday">Glenda Halliday</name>
<affiliation wicri:level="3"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Neuroscience Research Australia and the University of New South Wales, Sydney</wicri:regionArea>
<placeName><settlement type="city">Sydney</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University College London, Reta Lila Weston Institute of Neurological Studies, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pennsylvania Health Systems, Pennsylvania Hospital, Department of Neurology, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-05">2011-05</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1015">1015</biblScope>
<biblScope unit="page" to="1021">1021</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D3143478950ED27D311D670FCE4BA2216869276B</idno>
<idno type="DOI">10.1002/mds.23669</idno>
<idno type="ArticleID">MDS23669</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asymptomatic</term>
<term>Dopamine (metabolism)</term>
<term>History, 20th Century</term>
<term>History, 21st Century</term>
<term>Humans</term>
<term>Lewy Bodies (pathology)</term>
<term>Lewy bodies</term>
<term>Lewy body</term>
<term>Nervous system diseases</term>
<term>Neurons (metabolism)</term>
<term>Neurons (pathology)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (history)</term>
<term>Parkinson Disease (pathology)</term>
<term>Parkinson Disease (therapy)</term>
<term>Parkinson disease</term>
<term>neuropathology</term>
<term>preclinical Parkinson's disease</term>
<term>α‐synuclein</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="history" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lewy Bodies</term>
<term>Neurons</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>History, 20th Century</term>
<term>History, 21st Century</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Asymptomatique</term>
<term>Corps Lewy</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The identification of the widespread deposition of fibrillized α‐synuclein in Lewy bodies and Lewy neurites in the brains of patients with Parkinson's disease in 1997 has had a profound impact on how the disease is now conceptualized. The previous focus on the loss of the dopaminergic nigrostriatal system, the concept of subcortical dementia, and the idea that Parkinson's disease was dominated by motor impairment have all given way to research assessing more diverse brain regions, clinical symptoms, and phenotypes. It is now recognized that Parkinson's disease is more than just a loss of midbrain dopaminergic neurons in association with Lewy bodies. There are now several theories on how the disease develops and progresses currently being validated in a variety of studies, although many of these theories have yet to incorporate the phenotypic clinical and pathological changes associated with age. A particularly exciting new area of research involves the cell‐to‐cell transmission of pathogenic proteins. The recent consensus definition of Parkinson's disease dementia will allow its pathologic substrates to be determined. These advances have progressed to a stage where the preclinical stages of Parkinson's disease and its specific signs and symptoms are being predicted and tested clinically. Such strategies herald a future wave of preventive strategies for Parkinson's disease and its clinical symptoms. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Pennsylvanie</li>
</region>
<settlement><li>Londres</li>
<li>Sydney</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Halliday, Glenda" sort="Halliday, Glenda" uniqKey="Halliday G" first="Glenda" last="Halliday">Glenda Halliday</name>
</noRegion>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees (neurologue)</name>
</region>
</country>
<country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001561 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001561 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:D3143478950ED27D311D670FCE4BA2216869276B |texte= Milestones in Parkinson's disease—Clinical and pathologic features }}
This area was generated with Dilib version V0.6.23. |